Abbott Laboratories
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert B. Ford
- Full Time Employees
- 115,000
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 100 Abbott Park Road Abbott Park IL United States 60064-6400
- IPO Date
- Mar 1, 1937
- CIK
- 0000001800
- Website
- abbott.com
- Similar Companies
- Business
- Abbott Laboratories (NYSE: ABT) develops, manufactures, and sells a broad range of health care products worldwide. The company operates through four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices; its core offerings include branded generic pharmaceuticals such as Branded generics in emerging markets, anti-infectives, and gastrointestinal drugs; diagnostics encompassing point-of-care testing systems like i-STAT, molecular diagnostics via Alinity platforms, rapid diagnostics under BinaxNOW and Determine brands, and core laboratory instruments; nutritional products including pediatric formulas like Similac and Pediasure, adult nutritionals such as Ensure and Glucerna, and medical foods; as well as medical devices featuring cardiovascular and neuromodulation devices including FreeStyle Libre continuous glucose monitoring systems, Aveir leadless pacemakers, TactiFlex ablation catheters, and structural heart devices like Amplatzer occluders. Abbott serves health care professionals, consumers, hospitals, laboratories, and governments across more than 100 countries, with principal manufacturing facilities in the United States, Europe, Asia, and Latin America. Founded in 1888 and headquartered in Abbott Park, Illinois, the company maintains a diversified portfolio without notable subsidiaries or parent relationships impacting its core structure. In recent developments within the last two years, Abbott completed the acquisition of Cardiovascular Systems, Inc. in 2024 to expand its cardiovascular portfolio; launched the FreeStyle Libre 3 integrated continuous glucose monitoring sensor in multiple markets including the U.S.; introduced the AVEIR DR dual chamber leadless pacemaker system and the TactiFlex Sensor Enabled Ablation Catheter; formed strategic partnerships for digital health integrations and expanded diagnostics manufacturing capacity amid global demand surges; and reported strong growth in its diabetes and cardiovascular segments during 2025 earnings.
Company News
Abbott: 3 Key Takeaways for Long-Term Investors
Abbott Q3: Nutrition Spin-Out, Narrowed Guidance Rocks Stock; For Now, At Least
Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm
Abbott Laboratories (ABT) Q3 2026 Earnings Call Transcript
Abbott Laboratories (ABT) Reports Q3 Results and Plans Nutrition Business Spin-Off
What Abbott Laboratories (ABT) Said on Its Q3 Earnings Call
ABT Stock Down Post Q3 Earnings Miss, Revenues Rise Y/Y, Margins Up
Abbott (ABT) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Abbott (ABT) Misses Q3 Earnings Estimates
Abbott to Carve Out Nutrition Business Into Independent Company
Abbott lowers 2026 sales growth forecast on medical device weakness
Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company
How To Earn $500 A Month From Abbott Stock Ahead Of Q3 Earnings
2 Industries Beyond AI With Long-Term Demand Drivers for 2027
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q3 Earnings
The Winners Inside SCHD - October 2026
Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy.
Abbott Laboratories $ABT Stock: Banque Pictet & Cie SA Increases Stake
Countdown to Abbott (ABT) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS